BioLife Solutions, Inc. (BLFS) Income Statement
BLFS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBLFS revenue and net income
Where BLFS's revenue goes
2025Each bar shows an amount and its share of revenue. BLFS kept −12.6% of revenue as net income.
BLFS profit margins
BLFS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +17.0% | +8.1% | +14.9% | +31.0% |
| Gross profit | +15.7% | +9.8% | +20.5% | +32.2% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BLFS quarterly EPS vs estimates
BioLife Solutions beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 5, 2026 (estimate $0.01).
BLFS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $96.2M | $82.3M | $68.0M | $76.2M | $119.2M | $48.1M | $27.4M | $19.7M | $11.0M | $8.2M |
| Cost of revenue | $34.1M | $28.6M | $26.7M | $29.3M | $82.1M | $23.7M | $9.8M | $6.2M | $4.3M | $3.4M |
| Gross profit | $62.1M | $53.7M | $41.3M | $46.9M | $37.0M | $24.4M | $17.5M | $13.5M | $6.7M | $4.8M |
| Research & development | $7.6M | $7.9M | $5.5M | $14.8M | $11.8M | $6.7M | $4.1M | $1.3M | $1.2M | $2.0M |
| Sales, general & admin | $55.4M | $50.2M | $54.2M | $33.3M | $47.7M | $21.0M | $13.6M | $8.6M | $6.6M | $7.6M |
| Total operating expenses | $62.9M | $60.8M | $60.7M | $52.8M | $67.7M | $27.7M | $19.1M | $9.9M | $7.8M | $9.6M |
| Operating income | −$1.1M | −$7.1M | −$19.4M | −$5.9M | −$30.6M | −$3.3M | −$220,000 | $3.7M | −$1.1M | −$4.9M |
| Interest income | — | — | — | — | — | $58,000 | $506,000 | $281,000 | $350 | $2,420 |
| Interest expense | $2.7M | $719,000 | $1.8M | $687,000 | $485,000 | $18,000 | $5,000 | $5,000 | $190,069 | $318,394 |
| Income before taxes | −$12.1M | −$11.4M | −$12.2M | −$4.8M | −$29.0M | −$597,000 | −$3.2M | $3.3M | −$2.5M | −$8.0M |
| Income taxes | $49,000 | −$38,000 | −$64,000 | −$5.2M | −$20.1M | −$3.3M | −$1.5M | $396,000 | $1.5M | $1.6M |
| Net income | −$12.1M | −$20.2M | −$68.0M | −$139.8M | −$8.9M | $2.7M | −$1.7M | $3.3M | −$2.5M | −$6.9M |
| EBITDA | $3.6M | $1.5M | −$7.1M | $5.8M | −$17.8M | $1.7M | $2.6M | $4.0M | −$717,318 | −$7.4M |
| EPS (diluted) | −$0.21 | −$0.32 | −$1.06 | −$1.62 | −$0.67 | −$0.03 | $0.12 | $0.16 | −$0.16 | −$0.55 |
| Gross margin | 64.6% | 65.3% | 60.7% | 61.5% | 31.1% | 50.8% | 64.1% | 68.5% | 61.2% | 58.1% |
| Operating margin | −1.1% | −8.7% | −28.5% | −7.8% | −25.7% | −6.9% | −0.8% | 18.5% | −9.6% | −59.0% |
| Net margin | −12.6% | −24.5% | −100.0% | −183.4% | −7.5% | 5.5% | −6.1% | 16.5% | −22.8% | −83.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $28.5M | $27.5M | $18.8M | $28.1M | $25.4M | $23.9M | $0 | $30.6M | $19.7M | $18.4M | $32.7M | $23.6M |
| Cost of revenue | $10.2M | $10.1M | $6.1M | $10.1M | $9.0M | $8.2M | −$11.7M | $8.8M | $6.5M | $6.2M | $23.5M | $11.6M |
| Gross profit | $18.3M | $17.4M | $12.7M | $17.9M | $16.4M | $15.8M | $8.3M | $21.8M | $13.2M | $12.2M | $9.2M | $12.0M |
| Research & development | $3.0M | $2.6M | $66,000 | $2.7M | $2.7M | $2.2M | $1.1M | $2.0M | $2.0M | $3.5M | $4.4M | $3.7M |
| Sales, general & admin | $13.5M | $14.7M | $10.5M | $14.6M | $14.1M | $14.1M | $6.6M | $14.9M | $11.8M | $10.4M | $17.5M | $15.7M |
| Total operating expenses | $16.6M | $17.4M | $6.9M | $18.0M | $33.1M | $17.0M | $6.9M | $23.4M | $14.5M | $15.5M | $22.4M | $27.5M |
| Operating income | $1.7M | $27,000 | $5.8M | −$89,000 | −$16.6M | −$1.2M | $1.4M | −$1.6M | −$1.3M | −$3.3M | −$13.2M | −$15.5M |
| Interest income | $994,000 | $1.0M | — | — | $684,000 | $683,000 | — | — | — | — | — | — |
| Interest expense | — | — | $152,000 | $508,000 | $684,000 | — | $116,000 | $267,000 | $361,000 | $207,000 | $507,000 | $449,000 |
| Income before taxes | $2.8M | $1.2M | $3.4M | $703,000 | −$15.7M | −$434,000 | $1.5M | −$1.7M | −$5.6M | −$3.2M | −$13.4M | −$15.7M |
| Income taxes | −$42.4M | $62,000 | −$173,000 | $82,000 | $126,000 | $14,000 | −$131,000 | −$28,000 | $1,000 | $17,000 | −$43,000 | $115,000 |
| Net income | $45.1M | $1.2M | $3.5M | $621,000 | −$15.8M | −$448,000 | $12.5M | −$1.7M | −$20.7M | −$10.2M | −$13.4M | −$29.1M |
| EBITDA | $3.6M | $726,000 | $4.1M | $1.2M | −$14.3M | $166,000 | $6.7M | $853,000 | $1.1M | −$764,000 | −$3.6M | −$12.0M |
| EPS (diluted) | $0.04 | $0.04 | $0.04 | $0.04 | −$0.33 | $0.04 | −$0.02 | −$0.02 | −$0.05 | −$0.23 | −$0.21 | −$0.34 |
| Gross margin | 64.2% | 63.3% | 67.5% | 63.9% | 64.6% | 65.9% | — | 71.3% | 67.0% | 66.4% | 28.3% | 50.9% |
| Operating margin | 6.0% | 0.1% | 31.0% | −0.3% | −65.5% | −5.1% | — | −5.1% | −6.6% | −17.9% | −40.2% | −65.6% |
| Net margin | 158.4% | 4.3% | 18.8% | 2.2% | −62.3% | −1.9% | — | −5.6% | −105.1% | −55.4% | −40.9% | −123.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BLFS's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BLFS financial results
In fiscal year 2025 (ended December 31, 2025), BioLife Solutions reported revenue of $96.2 million, up 17.0% from the year before. It had a net loss of $12.1 million, a net profit margin of −12.6%. Diluted earnings per share came to −$0.21. Over five years revenue grew at an average rate of 14.9% a year.
See the BLFS stock overview for the latest quote and news, or the BLFS chart for price history and technical indicators.
BLFS income statement FAQ
What is BioLife Solutions's annual revenue?
BioLife Solutions reported total revenue of $96.2 million for fiscal year 2025, which ended on December 31, 2025. That was up 17.0% from $82.3 million the previous year.
Is BioLife Solutions profitable?
No. BioLife Solutions reported a net loss of $12.1 million in fiscal 2025, a net profit margin of −12.6%; its operating margin was −1.1%.
What is BioLife Solutions's gross margin?
BioLife Solutions's gross margin was 64.6% in fiscal 2025: for every $100 of revenue, BioLife Solutions kept $65 after the direct cost of its products and services.
How much does BioLife Solutions spend on research and development?
BioLife Solutions spent $7.6 million on research and development in fiscal 2025, 7.9% of revenue.
How fast is BioLife Solutions growing?
Revenue grew 14.9% a year on average over the last five fiscal years, from $48.1 million to $96.2 million.
What are BioLife Solutions's earnings per share?
BioLife Solutions earned $-0.21 per diluted share in fiscal 2025, compared with $-0.32 a year earlier.
When will BioLife Solutions report its next earnings?
BioLife Solutions is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does BioLife Solutions's fiscal year end?
BioLife Solutions's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.